| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 23 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 肥満 |
この研究の注釈：
In persons with Coronary Artery Disease, Pycnogenol at 200mg daily for 8 weeks is associated with an improvement of blood flow independent of changes in blood pressure
Reduction Of Cardiovascular Risk Factors In Subjects With Type 2 Diabetes By Pycnogenol Supplementation
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 45 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
この研究の注釈：
Supplementation of 125mg pycnogenol daily for 12 weeks in type II diabetics currently on ACE inhibitor therapy showed benefits to blood pressure in 58.3% of subjects by halving their required dosage of ACE inhibitor. Other biomarkers, such as endothelin-1, glucose, and HbA1c all decreased relative to placebo.
Supplementation of 125mg pycnogenol daily for 12 weeks in type II diabetics currently on ACE inhibitor therapy showed benefits to blood pressure in 58.3% of subjects by halving their required dosage of ACE inhibitor. Other biomarkers, such as endothelin-1, glucose, and HbA1c all decreased relative to placebo.
A reduction in urinary albumin was noted after two months but this may have reached significance due to a spike in the placebo group, both groups normalized within three months of supplementation and there was no significant differences at this time.
Most effects required two months of supplementation to manifest, maintaining in potency for the third month and not occurring within the first.
研究の資金源に関する問題点：
Study funded by Horphag research, producers of pycnogenol supplements